Skip to main content

The Costs of Innovation

From the series Industry and pharmaceuticals

The Trump administration wielded the sword of tariffs against pharmaceutical companies, with the declared aim of bringing productive activities back to America. The largest multinational life sciences firms responded with investment announcements — estimated to total $400 billion. It is not always clear whether these are entirely new allocations or whether they include capital already committed to earlier expansion plans in the US market. In any case, the expected increase in pharmaceutical manufacturing capacity in the US will take a few years to materialise. The administration nevertheless emphasised the Trump effect.

The relocation of production lines to existing or newly built plants relates to some branded drugs protected by patents. Generics, which account for 90% of prescriptions in America, are not affected.

Global supply chains

As already noted, the supply chain of medicines is long and complex. Consequently, the imposition of customs tariffs is equally complicated. In most cases, the production process does not occur entirely in a single country. Raw materials and active ingredients can come from different countries, as well as the formulation of the medicine and its final packaging (fill & finish) in tablets or solutions. A drug can pass through different plants and countries during its processing before eventually reaching the consumer. For example, AstraZeneca’s COVID-19 vaccine was produced in the Netherlands and Belgium and packaged in Anagni (Italy) by the US company Catalent.

US Pharmacopeia (USP) — a non-profit scientific organisation that tracks medicines and monitors their compliance with quality standards — has traced the origin of the active ingredients of drugs prescribed in the United States. For branded medicines, 15% of the active ingredient is produced in the US, 43% in the EU, 2% in India, and 3% in China, while the remaining 37% are classified as other or of unknown origin. In the case of generic medicines, the picture changes radically: 12% comes from the US domestic market, 18% from the EU, 35% from India, and 8% from China.

Branded drugs remain protected by patents, which last twenty years (plus any extensions that companies, often through various ruses, obtain from regulators). They therefore tend to include the most innovative products and, increasingly, biological treatments. Moving from active ingredients to finished drugs, considered as a whole, USP found that 22% of orally administered prescription medicines in the US are domestically produced, 6% come from the EU, 60% from India, and 3% from China.

On the other hand, almost half of injectable medicines are produced in the United States, with 45% of the total; 19% are produced in the EU, 15% in India, and 9% in China [The New York Times, August 23rd].

Unlikely self-sufficiency

The United States therefore depends on foreign countries primarily for generic drugs, which, as mentioned, account for nine out of ten prescriptions. For some medications, the dependence is almost total. For example, according to the analytics company Clarivate, China and India produce nearly all the active ingredients for the anti-inflammatory ibuprofen and the antibiotic ciprofloxacin, as well as the widely used amoxicillin. Just 19% of the anti-hypertensive losartan is produced as a finished drug in the US, while 78% is imported from India, and both countries rely on China for the active ingredient [The New York Times, April 4th].

According to a Clarivate survey, more than 80% of active ingredients for essential medicines do not have production facilities in the United States. This has caused shortages which peaked in 2011, when 267 medicines were unavailable on the national market [Center for Analytics and Business Insight-Washington University, “The US Active Pharmaceutical Ingredient Infrastructure: The Current State and Considerations to Increase US Healthcare Security”, August 1st, 2021].

It is understandable why active ingredients and generic drugs, at least for now, are not subject to US tariffs: not only could they cause price increases, but they could exacerbate existing shortages.

The Trump administration aims to bring pharmaceutical production back to the United States, including generics and active ingredients. It will be a complex endeavour. According to an analysis of data collected by the Food and Drug Administration (FDA), the number of US facilities formulating generic drugs has decreased by 27% since 2013, and plants producing active ingredients have fallen by 38% [The New York Times, November 4th]. Lower production costs in other countries have led to the closure of plants that are no longer competitive. Modernising them, or building new ones, requires years, significant investment and technological innovation to remain competitive. Moreover, the average cost of an American worker can be more than ten times higher than their Indian counterpart.

Tariffs vs prices

Branded medicines, being more recent and expensive, and generating higher profit margins, are the ones targeted by tariffs (currently at 15%). On drug prices, the Trump administration resumed a battle that the president had already undertaken, without success, during his first term. The Biden presidency had previously reached a historic agreement with Big Pharma.

In the United States, branded drugs cost two or three times as much as in Europe. The policy of multinational companies, so Trump accuses, is to load their high profits and their research and development (R&D) costs, which benefit the entire world, onto American consumers. The executive order of May 12th, which announced an aggressive price reduction plan, also targeted the bargaining system practised in the United States along the supply chain, among manufacturers and intermediaries, hospitals, insurance companies, and pharmacy chains, offering confidential discounts on list prices. The consulting firm Berkeley Research Group estimates that approximately half of pharmaceutical sales proceeds in the US are lost along the distribution chain [Handelsblatt, September 12th, 2025].

A lowering of prices in the United States is seen favourably by major pharmaceutical companies, as long as it reflects a realignment between the two sides of the Atlantic. We agree with Donald Trump’s goal of making medicines cheaper in the US, declared Christopher Boerner — the CEO of Bristol-Myers Squibb (BMS) — to the financial newspaper Handelsblatt. However, without a corresponding price increase in Europe, it would be a severe blow for European producers, as the American market is their main source of profits.

This is also the opinion of other multinational companies. I personally believe that the president is right to say that price equalisation should happen [...]. The cost of R&D in our industry should be shared more fairly across rich countries, says Pascal Soriot — the CEO of AstraZeneca — [The New York Times, July 31st]. The Anglo-Swedish company, which has its headquarters in the UK, halted the £450 million expansion of a vaccine factory in Liverpool earlier this year and has now decided not to expand its research site in Cambridge. US companies Eli Lilly and Merck have also suspended multi-million-dollar investments in research centres in London. Richard Torbett of the Association of the British Pharmaceutical Industry told Handelsblatt on September 25th that other companies are critically reviewing their investments in the UK and their future product plans.

New distribution models

According to Soriot, in hyper-regulated Europe, medicines are underpaid. You still see a large industrial base in Europe, for historical reasons. A problem is future products rely on new technologies that require new manufacturing tools. And these technologies are going to the US, and they’re going to China and other parts of the world, so in 15-20 years, Europe could easily lose its health sovereignty. At this rate, Soriot believes, companies will invest elsewhere and some European countries will only have access to generic drugs, over ten years old, and not to the new therapies [Financial Times, November 7th].

In the US Big Pharma — faced with tariffs and the threat of punitive measures, such as the accelerated approval of generic versions of highly profitable biological drugs — hurried to negotiate voluntary price reductions. Among the companies, the line of direct sales to the public, under medical prescription, is gaining ground, reducing the earnings of other operators in the distribution chain.

Among the first companies to adopt the new distribution model, Pfizer and AstraZeneca have reached an agreement with the administration for a reduction of up to 50% on some of their medicines, in exchange for a three-year moratorium on tariffs. These products will be sold directly online to consumers through TrumpRx, a platform specially created by the government which will be operational from January 2026. Other companies such as Novartis, BMS, Merck KGaA (Germany) are about to move to direct sales.

The enthusiasm is exaggerated, according to The New York Times, and it is not certain that the new distribution model will benefit the consumer. The few AstraZeneca drugs mentioned that will be sold on TrumpRx are not among the most prescribed in the United States. In the complex US distribution system, it can happen that an insured patient has a co-payment charge on a prescription which is lower than the new price if purchased directly.

The latest agreement was signed with the Danish company Novo Nordisk and Eli Lilly, the fiercely competing producers of the now famous, widely used and expensive GLP-1 anti-obesity drugs. A triumphant White House fact sheet announced on November 6th the latest in a series of most significant actions ever taken by the federal government to lower prices. Under the agreement, the price of Novo Nordisk’s Ozempic and Wegovy (semaglutide) will drop from $1,000 and $1,350 respectively to $350 for a monthly treatment. The price of Eli Lilly’s Zepbound (tirzepatide) and Orforglipron (still experimental) will drop from $1,086 to an average of $346 per month. The drugs can be reimbursed by the Medicare and Medicaid public health insurance programmes, if prescribed to obese patients with co-morbidities, with a co-payment of $50.

In the battle over prices, in the US as in Europe, what is at stake is the return (meaning profits) on capital invested in R&D, i.e., in innovation. This is where Asia comes into play.

Lotta Comunista, November 2025
Labels:

Popular posts in the last week

India’s Weaknesses in the Global Spotlight

Farmers’ protests around New Delhi have been going on for four months now. A controversial intervention by the Supreme Court has suspended the implementation of the new agticultural laws, but has raised questions about the dynamics between the judiciary and the executive, and has failed to unblock the negotiations between government and peasant organisations. The assault by Sikh farmers on the Red Fort during the Republic Day parade as India was displaying its military might to the outside world — the Chinese Global Times maliciously noted — paradoxically widened the protest in the huge state of Uttar Pradesh. The Modi government has been trying to revive India’s image with the 2021 Union Budget: it announced one hundred privatisations and approved the increase to 75% of the limit on direct foreign investment in insurance companies. For The Indian Express ( IEX ) this is a sign of the commitment to push ahead with reforms despite the backlash from rural India. Also for The Economi...
Read more

China’s Electromechanical Champions

Internationalism No. 85, March 2026 Page 9 From the series Major industrial groups in China Analysing the WTO data for 2023, it emerges that China exported goods worth $3,379 billion, surpassing the European Union and the United States. Industrial machinery accounted for over 7% of exports and electrical machinery 9%. In the same sectors, Chinese imports did not reach 40% of the value of exports, indicating that these are among the pillars of Beijing’s export economy. Sany Heavy Industry In this newspaper we have already examined the Chinese mechanical engineering giant Sinomach. But in the field of machine construction, Sany Heavy Industry also holds a prominent position, particularly in excavators, cranes, industrial elevators, and cement machinery. The company, based in Changsha (Hunan) since 1991, was founded by Liang Wengen, who had previously been an executive at a State-owned arms factory, and is its main shareholder. Sany had a 2023 turnover...
Read more

The Defeat in Afghanistan — a Watershed in the Cycle of Atlantic Decline

In crises and wars there are events which leave their mark on history because of how they make a decisive impact on the power contention, or because of how, almost like a chemical precipitate, they suddenly make deep trends that have been at work for some time coalesce. This is the case of the defeat of the United States and NATO in Afghanistan, which is taking the shape of a real watershed in the cycle of Atlantic decline. For the moment, through various comments in the international press, it is possible to consider its consequences on three levels: America’s position as a power and the connection with its internal crisis; the repercussions on Atlantic relations and Europe’s dilemmas regarding its strategic autonomy; and the relationship between the Afghan crisis and power relations in Asia, especially as regards India’s role in the Indo-Pacific strategy. Repercussions in the United States Richard Haass is the president of the CFR, the Council on Foreign Relations; despite having ...
Read more

Euro-solubility

Before capsules and pods, there was freeze-dried instant coffee powder, which of course tasted nothing like a real espresso. Now: for some time we have been following the vicissitudes of sovereigntists and populists with the idea that their political future depended on their Euro-solubility . Referring to the law-and-order, xenophobic and immigrant-hostile traits that have become common currency in European debates, we wrote that a Europe that protects could use the anti-immigration rhetoric of the sovereigntists to keep them on the leash of the pro-European strategic consensus. No sooner said that done. In Italy, as in France and other European countries, that phenomenon is in full swing. In Italy, the Five Star Movement has already embarked on its path to conversion a year and a half ago, entrusted with no less than the direction of Italian diplomacy. And even the Lega, believe it or not, has become a pro-European party overnight. In France, a similar process has seized Marine Le P...
Read more

The Unstoppable Force: Capital’s Demand for Migrant Labour

Internationalism No. 78-79, August-September 2025 Page 16 “Before Giorgia Meloni became Italy’s prime minister, she pledged to cut immigration. Since she has been in government the number of non-EU work visas issued by Italy has increased”. This is how The Economist of April 26th summarises the schizophrenia of their politics; and this is not only true in Italy: “Net migration also surged in post-Brexit Britain”. The needs of the economic system do not coincide with the rhetoric of parliamentarism. And vice versa. Schizophrenia and imbalances in their politics Returning to Italy, the Bank of Italy has pointed out that by 2040, in just fifteen years, there will be a shortage of five million people of working age, which could lead to an estimated 11% contraction in GDP. This is why even Italy’s “sovereignist” government is preparing to widen the net of its Immigration Flow Decree. The latest update, approved on June 30th, provides for the entry of almost ...
Read more

Democratic Defeat in the Urban Vote

Internationalism No. 71, January 2025 Page 2 From the series Elections in the USA A careful analysis of the 2022 mid-term elections revealed the symptoms of a Democratic Party malaise which subsequently fully manifested itself in the latest presidential election, with the heavy loss of support in its traditional strongholds of the metropolitan areas of New York City and Chicago, and the State of California. A defeat foretold Republican votes rose from 51 million in the previous 2018 midterms to 54 million in 2022, a gain of 3 million. The Democrat vote fell from 61 to 51 million, a loss of 10 million. The Republicans gained only three votes for every ten lost by the Democrats, while the other seven became abstentions. In 2022, we analysed the elections in New York City by borough, the governmental districts whose names are well known through movies and TV series. In The Bronx, where the average yearly household income is $35,000, the Democrats lost 52,00...
Read more

In the Depth of Our Class

The pandemic of the century is a storm that does not subside; it returns to its rampage after 40 million infections and more than a million official victims, perhaps two million according to estimates on the excess deaths. In the contention between powers, China stands as the winner: it seems to have tamed the virus, and industry and services are up and running; the USA and Europe, on the other hand, are moving towards a new wave of infections that casts yet more shadows on the economic cycle. Political structures and health systems are at the height of tension. In America, the elections have judged Donald Trump’s rash demagogy on the basis of the opposite reasons for containing the pandemic and the intolerance of small and large producers; in Europe the executives are attempting to steer between the surge in infections, increasingly stringent confinement measures and the threats of fiscal jacquerie in the tourism and catering sectors. Almost everywhere, in the Old Continent, governm...
Read more

Armed Negotiations between the Gulf and the Mediterranean

David Petraeus, Commander of the US forces in Iraq and the Gulf in 2007-2008, then director of the CIA in 2011-12, described the elimination of Iranian General Qasem Soleimani on January 3 rd in Baghdad as a defensive action , with which the Trump presidency restored a US deterrence , which was weakened by recent Iranian actions . This is a reference to the attacks conducted indirectly, unclaimed by Tehran, against the Saudi oil infrastructures on September 14 th 2019. In March 2008, when the forces under Petraeus’ command supported the Iraqi Army in the fight against local Shite militias, Soleimani sent a message to the American general: informing him that he was the person in charge for Iranian policies in Iraq, Syria, Lebanon and Gaza therefore the channel through which to define an agreement to resolve the various issues with Tehran. Petraeus holds the advisors of the Quds Force, the spearhead of the Pasdaran asymmetric operations, responsible for the killing of around 600 ...
Read more

Biden Plan and Global Minimum Tax

Recovery from the pandemic crisis — writes the IMF in April’s World Economic Outlook — is increasingly visible due to three factors: first, hundreds of millions of people are being vaccinated; second, companies and employees have somewhat adapted to the healthcare disaster; and finally governments especially the American have pledged massive government — extra fiscal support. Governmental fiscal interventions have reached $16,000 billion worldwide, have averted collapse of the economy that would have been three times worse, blocking the 2020 recession at a 3.3% drop, and have pushed the recovery rate to 6% in 2021. The overall recovery will be the outcome of a series of divergent recoveries . Only the United States, with a 6.4% growth rate, will exceed the GDP level predicted before the pandemic. The disparity regards healthcare first of all. High-income countries, representing 16% of global population, have already bought up half of the vaccine doses. The real estate, financial and ...
Read more

‘Two Hands’ and ‘Two Roads’

From the series News from the Silk Road The international tensions which China will face on the seas in the next fifteen years could find a buffer in the expansion of China’s influence on land in Central, Southern and Western Asia. Wang Jisi is the dean of the School of International Studies at the University of Beijing and a major figure of the American party in China. His unexpected foray into ‘geopolitics’ has reignited the old clash between different American currents — a phenomenon we analysed more than twenty years ago. At the time, Robert Manning, the author of The Asian Energy Factor and adviser to the State Department in 1991, viewed Asia’s growing dependence on the Persian Gulf for its energy requirements in the light of geoeconomics and geostrategy and foresaw a possible convergence between the USA and China. From a geoeconomic standpoint, both trade and the funding and development of the infrastructure necessary for Asia’s energy needs were more important than terri...
Read more